Breaking News

BIOCAD Launches New Mfg. Site in North Africa

Russian company will make biosimilars of rituximab and bevacizumab for cancer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Russian biotechnology company BIOCAD and Moroccan pharmaceutical company Sothema Labs have launched medicines derived using the technology provided by the Russian manufacturer into the North African market. The manufacturing of Russian biosimilars of rituximab and bevacizumab indicated for the treatment of cancer, approved in the first half of October 2017, will be based in Morocco. Besides Morocco, thеse biosimilars are planned to be marketed in Senegal, Gabon, and Côte d’Ivoire. The Russian...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters